Mankind Pharma Inks Exclusive Licensing Deal for Advanced Insulin Analogs

Mankind Pharma Limited has strengthened its presence in the diabetes-care segment by entering into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues—Insulin Degludec and Insulin Degludec + Aspart Combination—in India. The company announced the partnership on August 20, 2026, describing it as another step toward expanding its injectable diabetes portfolio and providing Indian patients with additional advanced treatment options.

Mankind Pharma Expands Diabetes Portfolio

The latest agreement is aimed at strengthening Mankind Pharma’s position in the injectable diabetes segment. Through the partnership, the company will commercialise Insulin Degludec and the Insulin Degludec + Aspart combination in India. According to the company, the addition of these products will complement its existing diabetes portfolio and support its broader strategy of increasing its presence in chronic therapies.

Partnership with Chinese Biopharmaceutical Company

The agreement has been signed with Chongqing Chenan Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company. Mankind Pharma said the partnership is part of its strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities. The company highlighted China’s rapidly developing biopharmaceutical ecosystem as a potential source of differentiated and innovative assets that can complement its existing product portfolio in India.

Focus on Injectable Diabetes Therapies

The addition of the two insulin products is particularly relevant to Mankind Pharma’s strategy of expanding its presence in chronic therapeutic areas. The company already operates across several therapeutic segments, including anti-diabetic, cardiovascular, gastrointestinal, anti-infectives, neuro/CNS, respiratory, gynaecology and other areas. The latest agreement provides another opportunity to broaden its offering in diabetes care, with a specific focus on injectable therapies.

Management Commentary

Commenting on the partnership, Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma, said that China is rapidly emerging as a hub for innovative biopharmaceutical assets. He noted that, building on the company’s partnerships for Insulin Aspart and Insulin Degludec, Mankind Pharma remains focused on expanding its in-licensing pipeline from China. According to the company, the partnership is intended to improve access to advanced therapies for Indian patients while further strengthening Mankind Pharma’s presence in the injectable diabetes segment.

Strategic Importance for Mankind Pharma

The agreement fits into Mankind Pharma’s broader strategy of combining its strong domestic commercial and distribution capabilities with products sourced through global partnerships. Rather than relying solely on internal product development, the in-licensing model can allow the company to add differentiated therapies to its portfolio while leveraging its established sales and distribution infrastructure in India. The company stated that the partnership further reinforces its commitment to expanding its diabetes portfolio and addressing the evolving treatment needs of patients.

Mankind Pharma’s Domestic Scale

Mankind Pharma describes itself as one of India’s leading pharmaceutical companies, with a strong focus on the domestic market. Following the acquisition of BSV, the company has also strengthened its position in women’s healthcare. According to the information provided in the release, Mankind Pharma has a field force of 18,500+ professionals, reaches more than five lakh doctors, and operates 32 manufacturing facilities across India. Its research and development network includes seven dedicated R&D facilities supported by more than 740 scientists.

Future Outlook

The latest in-licensing agreement indicates that Mankind Pharma intends to continue expanding its chronic-care and injectable portfolio through strategic partnerships. The company is particularly focused on leveraging international innovation and bringing additional treatment options to the Indian market. The commercial success of the newly licensed insulin products will ultimately depend on factors such as regulatory approvals, product launch timelines, market adoption, pricing, competition, and execution by the company’s sales and distribution network.

Key Points to Watch

• Mankind Pharma has entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical.
• The agreement covers Insulin Degludec and Insulin Degludec + Aspart Combination for India.
• The partnership strengthens Mankind Pharma’s injectable diabetes portfolio.
• The company is continuing to expand its presence in chronic therapeutic areas.
• China is becoming an important source of biopharmaceutical in-licensing opportunities for Mankind Pharma.
• The company already has partnerships involving Insulin Aspart and Insulin Degludec.
• Mankind Pharma plans to leverage its established Indian commercial and distribution network for its expanding portfolio.
• The company has 18,500+ field-force professionals and reaches more than five lakh doctors, according to the release.
• The agreement is part of a broader strategy focused on global innovation, strategic partnerships and in-licensing.
• The financial contribution and commercial impact of the newly licensed products were not disclosed in the press release.

Conclusion

Mankind Pharma’s exclusive in-licensing agreement for Insulin Degludec and Insulin Degludec + Aspart represents another step in the company’s efforts to build a stronger presence in India’s diabetes and injectable-therapy markets. The partnership also highlights Mankind Pharma’s increasing focus on using global collaborations to expand its product pipeline. While the company has not disclosed the financial terms or expected revenue contribution from the agreement, the deal adds new products to its diabetes portfolio and provides another potential growth opportunity as it increases its focus on chronic therapies.